WO2014011210A1 - Aav-mediated gene therapy for rpgr x-linked retinal degeneration - Google Patents
Aav-mediated gene therapy for rpgr x-linked retinal degeneration Download PDFInfo
- Publication number
- WO2014011210A1 WO2014011210A1 PCT/US2013/022628 US2013022628W WO2014011210A1 WO 2014011210 A1 WO2014011210 A1 WO 2014011210A1 US 2013022628 W US2013022628 W US 2013022628W WO 2014011210 A1 WO2014011210 A1 WO 2014011210A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- gene
- composition
- aav
- rpgr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
Definitions
- Photoreceptors function cooperatively with the retinal pigment epithelium (RPE) to optimize photon catch and generate signals that are transmitted to higher vision centers and perceived, as a visual image. Disruption of the visual process in the retinal photoreceptors can result in blindness. Genetic defects in the retina cause substantial numbers of sight-impairing disorders by a multitude of mechanisms.
- RPE retinal pigment epithelium
- XLRP Retinitis Pigmentosa GTPase Regulator
- RPGR RPGR gene account for >70 % of the cases of XLRP, and exon ORF 15, a mutational hot spot in RPGR, is mutated in 22-60% of patients. The disease is relentlessly progressive, and by the end of their fourth decade most patients are legally blind.
- RPGR-XLRP X-linked progressive retinal atrophy 1
- XLPRA2 (del 1084-1085) causes a frameshift, and inclusion of 34 basic amino acids that changes the isoelectric point of the putative protein, and truncates the terminal 161 residues.
- the disease is early onset and rapidly progressive. Both models correspond to the disease spectrum of human XLRP, and, although differing in relative severity, they would be equivalent to human disease occurring within the first decade of life. No successful treatment for XLRP is currently available to human patients suffering from this disease. What is needed is a treatment for RPGR-XLRP that is effective, safe and has long-term stability.
- the invention provides a method of preventing, arresting progression of or ameliorating vision loss associated with retinitis pigmentosa in a subject.
- the method includes administering to the subject an effective concentration of a composition comprising a recombinant adeno-associated virus (rAAV) carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- rAAV recombinant adeno-associated virus
- a method of preventing or arresting progression of photoreceptor function loss, or increasing photoreceptor function in a subject in need thereof includes administering to the subject an effective concentration of a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR. gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the subject's ocular cells, and a pharmaceutically acceptable carrier.
- a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR. gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the subject's ocular cells, and a pharmaceutically acceptable carrier.
- the invention provides a method of improving photoreceptor structure in a subject in need thereof.
- the method includes administering to the subject an effective concentration of a composition comprising a rAAV can ing a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- a composition comprising a rAAV can ing a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- a method of preventing, arresting progression of or ameliorating outer plexiform layer (OPL) abnormalities in a subject in need thereof includes administering to the subject an effective concentration of a composition comprising a rAAV carrying a nucleic acid sequence encoding a norma! RPGR gene, or fragment thereof, und er the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- OPL outer plexiform layer
- the invention provides a method of preventing, arresting progression of or ameliorating bipolar cell dendrite retraction in a subject in need thereof.
- the method includes administering to the subject an effective concentration of a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- a method of preventing, arresting progression of or ameliorating bipolar cell function loss in a subject in need thereof includes administering to said subject an effective concentration of a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- the invention provides a method of preventing, arresting progression of or ameliorating axonal injury characterized by overexpression of neurofilaments in a subject in need thereof.
- the method includes administering to the subject an effective concentration of a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable earner.
- a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable earner.
- a method of preventing XLRP in a subject at risk of developing the disease includes administering to the subject an effective concentration of a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- the invention provides a method of preventing, arresting or ameliorating rod and/or R/ ' G cone opsin mislocalization in a subject in need thereof.
- the method includes administering to the subject an effective concentration of a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in t e ocular cells of the subject, and a p armaceutically acceptable carrier.
- a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in t e ocular cells of the subject, and a p armaceutically acceptable carrier.
- the in vention pro vides a method of preventing, arresting progression of or ameliorating OPL synaptic changes, bipolar cell abnormaiities or inner retinal abnormalities associated with X-3 inked retinitis pigmentosa (XLRP) in a subject in need thereof.
- XLRP X-3 inked retinitis pigmentos
- the method includes administering to the subject an effective concentration of a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the subject's ocular cells, and a pharmaceutically acceptable carrier.
- a composition comprising a rAAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the subject's ocular cells, and a pharmaceutically acceptable carrier.
- the invention provides a method of increasing or preserving ONL thickness associated with XLRP in a subject in need, thereof.
- the method includes administering to said subject an effective concentration of a composition comprising a r AAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- a composition comprising a r AAV carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- a method of treating or preventing XLRP in a subject in need thereof includes (a) identifying subject having, or at risk of developing, XLRP; (b) performing genotypic analysis and identifying a mutation in the RPGR gene; (c) performing non-invasive retinal imaging and functional studies and identifying areas of retained photoreceptors that could be targeted, for therapy; and.
- composition comprising a recombinant virus carrying a nucleic acid sequence encoding a normal photoreceptor cell- specific gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier, thereby preventing, arresting progression of or ameliorating XLRP.
- the invention provides a composition
- a composition comprising a recombinant adeno-associated virus (rAAV) carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells of the subject, and a pharmaceutically acceptable carrier.
- rAAV recombinant adeno-associated virus
- the invention provides a composition including a recombinant AAV2/5 pseudo yped adeno-associated virus, carrying a nucleic acid sequence encoding a normal RPGR. gene, or fragment thereof, under the control of a human IRBP or human GRKl promoter which directs expression of the product of the gene in the ocular cells of the subject, formulated with, a carrier and additional components suitable for injection.
- a composition including a recombinant AAV2/5 pseudo yped adeno-associated virus, carrying a nucleic acid sequence encoding a normal RPGR. gene, or fragment thereof, under the control of a human IRBP or human GRKl promoter which directs expression of the product of the gene in the ocular cells of the subject, formulated with, a carrier and additional components suitable for injection.
- any of the methods described above utilizes this composition, BRIEF DESCRIPTION OF THE FIGURES
- Figure i is a plasrnid map of the AAV2/5 vector incorporating the hIRPB promoter (SEQ ID NO: 2) and hRPGRl-ORF15 gene.
- the IRBP promoter in this plasrnid is a 2 1 bp fragment of the proximal promoter region of the human IRBP gene.
- Figure 2 is a plasrnid map of the AAV2/5 vector incorporating the hGRKl promoter (SEQ ID NO: 3) and RPGR! -ORF IS gene.
- Figure 3 is an alignment of the nucleic acid sequence encoding human RPGR. variant SEQ ID NO: 1 (bottom) and the nucleic acid sequence encoding variant BK005711 (Wright) SEQ ID NO: 4 (top).
- Figure 4 is an alignment of the amino acid, sequence of human RPGR variant SEQ ID NO: 5 (top) and the amino acid sequence of variant BK00571 1 (Wright) SEQ ID NO: 6 (bottom).
- Figure 5 shows an alignment of amino acid residues aa 845-1039 of hRPGR.
- the present invention relates to various compositions and treatment methods utilizing the same comprising an effective concentration of a recombinant adeno- associated virus (rAAV) carrying a nucleic acid, sequence encoding a normal RPGK gene, or fragment thereof, under the control of regulatory sequences which direct expression of the product of the gene in the subject's ocular cells, formulated with a carrier and additional components suitable for injection.
- rAAV recombinant adeno- associated virus
- the treatment methods are directed to ocular disorders and associated conditions related thereto.
- a or “an” refers to one or more, for example, "a gene” is understood to represent one or more such genes.
- the terms “a” (or “an”), “one or more,” and. “at least one” are used interchangeably herein.
- the term “about” means a variability of 10 % from the reference given, unless otherwise specified..
- compositions herein described are useful, in another embodiment, in the methods of the invention.
- compositions herein described as useful in the methods is, in another embodiment, itself an embodiment of the invention. While various embodiments in the specification are presented using “comprising” language, under other circumstances, a related, embodiment is also intended to be interpreted and described using “consisting of or “consisting essentially of” language.
- the term "mammalian subject” or “subject” includes any mammal in need of these methods of treatment or prophylaxis, including particularly humans. Other mammals in need of such treatment or prophylaxis include dogs, cats, or other domesticated animals, horses, livestock, laboratory animals, including non-human primates, etc.
- the subject may be male or female.
- the subject has, or is at risk of developing, RP and more particularly, XLRP.
- the subject is a "carrier" for XLRP. i.e., has at least one RPGR mutation in at least one X chromosome.
- XLRP is an X-linked disease
- females which normally have two X chromosomes, may be homozygous or heterozygous for a specific mutation in the RPGR. gene, or compound eterozygotes, which have a different mutation in the RPGR gene on each X chromosome.
- Normal males, having only one X chromosome, with a mutation in the RPGR gene are termed hemizygous.
- the subject having, or at risk of developing XLRP is a hemizygous male.
- the subject having, or at risk of developing XLRP is a homozygous female or a heterozygous female.
- subjects at risk of developing XLRP include those with a family history of XLRP, those with one or more confirmed mutations in the RPGR gene, offspring of female carriers of an RPGR mutation (heterozygous females), or offspring of females carrying an RPGR mutation on both X chromosomes.
- the subject has shown clinical signs of XLRP.
- Clinical signs of XLRP include, but are not limited to, d ecreased peripheral vision, decreased central (reading) vision, decreased night vision, loss of color perception, reduction in visual acuity, decreased photoreceptor function, pigmentary changes.
- the subject has been diagnosed with XLRP.
- the subject has not yet shown clinical signs of XLRP.
- the subject has 10% or more photoreceptor damage/loss. In another embodiment, the subject has 20% or more photoreceptor damage/loss. In another embodiment, the subject has 30% or more photoreceptor damage/loss. In another embodiment, the subject has 40% or more photoreceptor damage/loss. In another embodiment, the subject has 50% or more photoreceptor damage/loss. In another embodiment, the subject has 60% or more photoreceptor damage/loss. In another embodiment, the subject has 70% or more photoreceptor damage/loss. In another embodiment, the subject has 80% or more photoreceptor damage/loss. In another embodiment, the subject has 90% or more photoreceptor damage/loss.
- the methods herein relate to the treatment or prevention of retinitis pigmentosa (RP).
- the retinitis pigmentosa is an X-linked retinitis pigmentosa (XLRP).
- XLRP is one of the most severe forms of RP, demonstrating an early age of onset (usually within the first decade) and rapid progression of disease. Because the disease is X-linked, homozygous females are rare, usually only manifesting in small, isolated populations. Thus, the disease primarily affects males, although carrier
- RPGR retinitis pigmentosa GTPase regulator
- the protein contains a RCC-1 like domain, characteristic of the highly conserved guanine nucleotide exchange factors.
- the constitutive transcript of RPGR containing 19 exons, is expressed. in a wide variety of tissues (Hong and Li. Invest Opthalmology Vis Sci, 43(1 1):3373-82, incoiporated by reference herein).
- An RPGR variant terminates in intron 15 of the RPGR gene.
- the alternative terminal exon consists of the constitutive exon 15 and part of intron 1 , and is termed ORF15.
- This protein isoform that is encoded by exons 1 through ORF 15 is used prevalently in photoreceptors and a large number of disease causing mutations have been found in ORF15 (Vervoort and Wright, Hum Mutat. 2002 May, 19(5):486-500; Aguirre et al, Exp Eye Res, 2002, 75:431-43; and Neidhardt et al, Hum Mutat. 2007, 28(8): 797 -8Q7, each of which is hereby incorporated by reference herein).
- the method employs a nucleic acid sequence encoding a normal RPGR. gene, or fragment thereof.
- RPGR refers to the full length gene itself or a functional fragment, as further defined, below.
- the nucleic acid sequence encoding a normal RPGR gene may be derived from any mammal which natively expresses the RPGR gene, or homolog thereof.
- the RPGR gene sequence is derived from the same mammal that the composition is intended to treat.
- the RPGR is derived from a human.
- the RPGR sequence is the sequence of the full length human RPGRORF15 clone, which includes exons .1 though ORE 15 (Vervoort R, et al. (2000), Nat Genet 25:462-466, which is incorporated by reference herein).
- the RPGR sequence is that shown in SEQ ID NO: 1.
- the RPGR sequence is a timctional fragment of the RPGRORF15 clone.
- fragment or “functional fragment” it is meant any fragment that retains the function of the full length clone, although not necessarily at the same le el of expression or activity.
- acDNA representing RPGR-ORF 15 but shortened by 654 bp in the repetitive region has been shown to reconstitute RPGR function in mice.
- Similar functional fragments of human, or other RPGR sequences may be determined by one of skill in the art.
- the RPGR is derived from a canine. lit other embodiments, certain modifications are made to the RPG sequence in order to enhance the expression in the target cell. Such modifications include codon optimization, (see, e.g., US Patent os.
- ocular cells refers to any cell in, or associated with the function of, the eye.
- the term may refer to any one of photoreceptor cells, including rod, cone and photosensitive ganglion cells or retinal pigment epithelium (RPE) cells.
- the ocular cells are the photoreceptor cells.
- the RPGR. nucleic acid sequence, or fragment thereof is delivered to the ocular ceils in need of treatment by means of a viral vector, of which many are known and available in the art.
- the therapeutic vector is desirably non-toxic, non-immunogenic, easy to produce, and efficient in protecting and delivering DNA into the target cells.
- the viral vector is an adeno-associated virus vector.
- the invention provides a therapeutic composition comprising an adeno-associated viral vector comprising an RPGR sequence under the control of a suitable promoter.
- the RPGR sequence is encoded by SEQ ID NO: 1.
- AAV viruses may be engineered by conventional molecular biology techniques, making it possible to optimize these particles for cell specific delivery of RPGR nucleic acid sequences, for minimizing
- RPGR overexpression can be achieved in the ocular cells through deliver by recombinantly engineered AAVs or artificial AAV's that contain sequences encoding RPGR.
- AAVs are a common mode of exogenous delivery of DNA as it is relatively non-toxic, pro vides efficient gene transfer, and can be easily optimized for specific purposes.
- human serotype 2 is the first AAV that was developed as a gene transfer vector; it has been widely used for efficient gene transfer experiments in different target tissues and animal models.
- AAV2 based vectors to some human disease models are in progress, and include such diseases as cystic fibrosis and hemophilia B.
- Other AAV serotypes include, but are not limited to, AAVl, AAV3, AAV4, AAV5, AAV 6, AAV7, AAVS and AAV9. See, e.g., WO 2005/033321 for a discussion of various AAV serotypes, which is incorporated herein by reference.
- Desirable AAV fragments for assembly into vectors include the cap proteins, including the v l , vp2, vp3 and hypervariable regions, the rep proteins, including rep 78, rep 68, rep 52, and rep 40, and the sequences encoding these proteins. These fragments may be readily utilized in a variety of vector systems and host cells. Such fragments maybe used, alone, in combination with other AAV serotype sequences or fragments, or in combination with elements from other AAV or non-AAV viral sequences.
- artificial AAV serotypes include, without limitation, AAV with a non-naturally occurring capsid protein. Such an artificial capsid may be generated by any suitable technique.
- AAV sequence e.g., a fragment of a vpl capsid protein ⁇ in combination with heterologous sequences which may be obtained from a different selected AAV serotype, non-contiguous portions of the same AAV serotype, from a non- AAV viral source, or from a non-viral source.
- An artificial AAV serotype may be, without limitation, a pseudotyped AAV, a chimeric AAA' ' capsid, a recombinant AAV capsid, or a
- AAV2/5 is used in the examples described below.
- the AAV is AAV2/5.
- the AAV is AAV2/8. See, Mussolmo et al, cited above.
- the vectors useful in compositions and methods described herein contain, at a minimum, sequences encoding a selected AAV serotype capsid, e.g., an AAV5 capsid, or a fragment thereof.
- useful vectors contain, at a minimum, sequences encoding a selected AAV serotype rep protein, e.g., AAV 5 rep protein, or a fragment thereof.
- such vectors may contain both AAV cap and rep proteins.
- the AAV rep and AA V cap sequences can both be of one serotype origin, e.g., all AAV5 origin.
- vectors may be used in which the rep sequences are from an AAV serotype which differs from that which is providing the cap sequences.
- the rep and cap sequences are expressed from separate sources (e.g., separate vectors, or a host cell and a vector).
- these rep sequences are fused in frame to cap sequences of a different AAV serotype to form a chimeric AAV vector, such as AAV2/8 described in US Patent No. 7,282,199, which is incorporated by reference herein.
- a suitable recombinant adeno-assoeiated virus is generated by culturing a host cell which contains a nucleic acid sequence encoding an adeno-associated virus (AAV) serotype capsid protein, or fragment thereof, as defined herein; a functional rep gene; a mmigene composed of, at a minimum, AAV inverted terminal repeats (IT s) and a RPGR nucleic acid sequence; and sufficient helper functions to permit packaging of the minigene into the AAV capsid. protein.
- the components required to be cultured in the host cell to package a AAA' ' minigene in an AAV capsid may be provided to the host cell in trans.
- any one or more of the required components may be provided by a stable host cell which has been engineered to contain one or more of the required components using methods known to those of skill in the art.
- such a stable host cell will contain the required component(s) under the control of an inducible promoter.
- the required component(s) may be under the control of a constitutive promoter.
- suitable inducible and constitutive promoters are provided herein, in the discussion below of regulator ⁇ ' elements suitable for use with the transgene, i.e., RPGR.
- a selected stable host ceil may contain selected components) under the control of a constitutive promoter and other selected components) under the control of one or more inducible promoters.
- a stable host cell may be generated which is derived from 293 cells (which contain El helper functions under the control of a constitutive promoter), but which contains the rep and/or cap proteins under the control of inducible promoters. Still other stable host cells may be generated by one of skill in the art.
- the minigene, rep sequences, cap sequences, and helper functions required for producing the rAAV of the invention may be delivered to the packaging host cell in the form of any genetic element which transfers the sequences carried thereon.
- the selected genetic element may be delivered by any suitable method, including those described herein.
- the methods used to construct any embodiment of this invention are known to those with skill in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY.
- methods of generating rAAV virions are well known and the selection of a suitable method is not a limitation on the present invention. See, e.g., K. Fisher et al, 1993 J. Virol, 70:520-532 and US Patent 5,478,745, among others. These publications are incorporated by reference herein.
- the AAV ITRs, and other selected AAV components described herein may be readily selected from among any AAV serotype, including, without limitation, AAVl, AAV2, A .V3, AAV , AAV5, AAV6, AAV7, AAV 8, AAV9 or other known and. unknown AAV serotypes.
- These ITRs or other AAV components may be readily isolated using techniques available to those of skill in the art from an AAV serotype.
- Such AAV may be isolated or obtained from academic, commercial, or public sources (e.g.. the American Type Culture Collection, Manassas, VA).
- the AAV sequences may be obtained through synthetic or other suitable means by reference to published sequences such as are available in the literature or in databases such as, e.g., GenBank, PubMed, or the like.
- the minigene is composed of, at a minimum, a RPGR nucleic acid sequence (the transgene), as described above, and its regulatory sequences, and 5' and 3' AAV inverted terminal repeats (ITRs).
- the ITRs of AAV serotype 2 are used. However, ITRs from other suitable serotypes may be selected. It is this minigene which is packaged into a capsid protein and delivered to a selected host cell.
- the regulatory sequences include conventional control elements which are operabiy linked to the RFGR gene in a manner which permits its transcription, translation and/or expression in a cell transfected with the vector or infected with the virus produced by the invention.
- operbiy linked sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest.
- Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product.
- RNA processing signals such as splicing and polyadenylation (polyA) signals
- sequences that stabilize cytoplasmic mRNA sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product.
- polyA polyadenylation
- a great number of expression control sequences, including promoters, are known in the art and may be utilized.
- the regulatory sequences useful in the constructs of the present invention may also contain an intron, desirably located between the promoter/ enhancer sequence and the gene.
- One desirable intron sequence is derived from SV-40, and is a 100 bp mini-nitron splice donor/splice acceptor referred to as SD-SA.
- Another suitable sequence includes the woodchuck hepatitis virus post-transcriptional element. (See, e.g., L. Wang and I. Verma, 1999 Proc. Natl. Acad. Sci . US A, 96:3906-3910).
- Poly A signals may be derived from many suitable species, including, without limitation SV-40, human and bovine.
- IRES internal ribosome entry site
- IRES (or other suitable sequence) is used to produce a protein that contains more than one polypeptide chain or to express two different proteins from or within the same cell.
- An exemplary IRES is the pofiovirus internal ribosome entry sequence, which supports transgene expression in photoreceptors, RPE and ganglion cells.
- the IRES is located 3' to the transgene in the rAAV vector.
- the selection of the promoter to be employed in the r AAV may be made from among a wide number of constitutive or inducible promoters that can express the selected transgene in the desired an ocular cell.
- the promoter is cell- specific.
- the term "cell-specific" means that the particular promoter selected for the recombinant vector can direct expression of the selected transgene in a particular ocular cell type.
- the promoter is specific for expression of the transgene in photoreceptor cells.
- the promoter is specific for expression in the rods and cones.
- the promoter is specific for expression in the rods.
- the promoter is specific for expression in the cones.
- the promoter is specific for expression of the transgene in RPE cells.
- the transgene is expressed in any of the above noted ocular cells.
- the promoter may be derived from any species.
- the promoter is the human G-protein-coupIed receptor protein kinase 1 (GRK1) promoter (Genbank Accession number AY327580),
- the promoter is a 292 nt fragment (positions 1793-2087) of the GRK 1 promoter (SEQ ID NO: 2) (See also, Beltran et al, Gene Therapy 2010 17: 1 162-74, which is hereby incorporated by reference herein).
- the promoter is the human interphotoreceptor retinoid-binding protein proximal (IRBP) promoter.
- the promoter is a 235 nt fragment of the hIRBP promoter (SEQ ID NO: 3). In another embodiment, promoter is the native promoter for the gene to be expressed. In one embodiment, the promoter is the RPGR proximal promoter (Shu et al, 10 VS, May 2102, which is incorporated by reference herein).
- promoters useful in the invention include, without limitation, the rod opsin promoter, the red-green opsin promoter, the blue opsin promoter, the cGMP-p-pliosphodiesterase promoter, the mouse opsin promoter (Beltran et al 2010 cited above), the rhodopsin promoter (Mussolino et al, Gene Ther, July 201 1 , 1 8(7):637-45); the alpha-subunit of cone transducin (Morrissey et al, BMC Dev, Biol, Jan 201 1, 11 :3); beta phosphodiesterase (PDE) promoter; the retinitis pigmentosa (RP1) promoter (Nicord et al, J.
- the promoter is of a small size, under 1000 bp, due to the size limitations of the AAV vector.
- the promoter is under 400 bp.
- constitutive promoters useful in the invention include, without limitation, the retroviral Rous sarcoma vims (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer), the SV40 promoter, the dihydrofoiate reductase promoter, the chicken ⁇ -actin (CBA) promoter, the phosphogiycerol kinase (PGK) promoter, the EF lpromoter
- RSV Rous sarcoma vims
- CMV cytomegalovirus
- CBA CBA
- PGK phosphogiycerol kinase
- inducible promoters allow regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of a specific physiological state, e.g., acute phase, a particular differentiation state of the cell, or in replicating ceils only.
- inducible promoters and. inducible systems are available from a variety of commercial sources, including, without limitation, Invitrogen, Clo tech and Ariad. Many other systems have been described and can be readily selected by one of skill in the art.
- inducible promoters regulated by exogenously supplied compounds include, the zinc-inducible sheep metalioihionine (MX) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system; the ecdysone insect promoter, the tetracycline-repressible system, the tetracycline-inducible system, the RU486-inducible system and the rapamycin-inducible system.
- MX zinc-inducible sheep metalioihionine
- Dex dexamethasone
- MMTV mouse mammary tumor virus
- inducible promoters which may be useful in this context are those which are regulated by a specific physiological state, e.g., temperature, acute phase, a particular differentiation state of the cell, or in replicating cells only. Any type of inducible promoter which is tightly regulated and is specific for the particular target ocular cell type may be used.
- Enhancer sequences useful in the invention include the 1RBP enhancer (Nicord 2007, cited above), immediate early cytomegalovirus enhancer, one derived from an immunoglobulin gene or SV40 enhancer, the cis-acting element identified in the mouse proximal promoter, etc.
- the recombinant AAV containing the desired transgene and cell-specific promoter for use in the target ocular ceils as detailed above is preferably assessed for contamination by conventional methods and then formulated into a pharmaceutical composition intended for subretinal injection.
- a pharmaceutically and/or physiologically acceptable vehicle or carrier particularly one suitable for administration to the eye, e.g., by subretinal injection, such as buffered saline or other buffers, e.g., HEPES, to maintain pH at appropriate physiological levels, and, optionally, other medicinal agents, pharmaceutical agents, stabilizing agents, buffers, carriers, adjuvants, diluents, etc.
- the carrier will typically be a liquid.
- physiologically acceptable carriers include sterile, pyrogen-free water and sterile, pyrogen-free, phosphate buffered saline. A variety of such known carriers are provided in US Patent Publication No.
- the carrier is an isotonic sodium chloride solution. In another embodiment, the carrier is balanced salt solution. In one embodiment, the carrier includes tween. If the virus is to be stored long-term, it may be frozen in the presence of glycerol or Tween20.
- the pharmaceutical composition described above is administered, to the subject by subretinal injection.
- subretinal injection as the route of delivery is a critical component of this method, as intravitreal administration currently does not enable the same therapeutic effects.
- non-invasive retinal imaging and functional studies it is desirable to perform non-invasive retinal imaging and functional studies to identify areas of retained photoreceptors to be targeted for therapy.
- clinical diagnostic tests are employed, to determine the precise location(s) for one or more subretinal injection(s). These tests may include electroretinography (ERG),perimetry, topographical mapping of the layers of the retina and measurement of the thickness of its layers by means of confocal scanning laser ophthalmoscopy (eSLO) and optical coherence tomography (OCT), topographical mapping of cone density via adaptive optics (AO), functional eye exam, etc.
- one or more injections are performed in the same eye in order to target different areas of retained photoreceptors.
- the volume and viral titer of each injection is determined individually, as further described below, and may be the same or different from other injections performed in the same, or contralateral, eye.
- a single, larger volume injection is made in order to treat the entire eye.
- the volume and concentration of the rAAV composition is selected so that only the region of damaged photoreceptors is impacted.
- the volume and/or concentration of the rAAV composition is a greater amount, in order reach larger portions of the eye, including non-damaged photoreceptors.
- the composition may be delivered in a volume of from about 50 ⁇ ih to about 1 ml.,, including all numbers within the range, depending on the size of the area to be treated, the viral titer used, the route of administration, and the desired effect of the method.
- the volume is about 50 uL.
- the volume is about 70 ,uL,
- the volume is about 100
- the volume is about 125 ,uL,
- the volume is about 150 ,uL.
- the volume is about 175 ⁇ L ⁇
- the volume is about 200 ⁇ .
- the volume is about 250 iL.
- the volume is about 300 ⁇ ...
- the volume is about 450 ⁇ ,. In another embodiment, the volume is about 500 ⁇ iL. In another embodiment, the volume is about 600 uL. In another embodiment, the volume is about 750 p,L. In another embodiment, the volume is about 850 ⁇ . In another embodiment, the volume is about 1000 ⁇ . ⁇ .
- An effective concentration of a recombinant adeno-assoeiated virus carrying a nucleic acid sequence encoding the desired transgene under the control of the cell-specific promoter sequence desirably ranges between about 10 8 and 10 i3 vector genomes per milliliter (vg/mL). The rAAV infectious units are measured as described in S.K. McLaughlin et al, 1988 J.
- the concentration is from about 1.5 x 10 9 vg/mL to about 1.5 x 10 12 vg/mL, and more preferably from about 1.5 x 10 9 vg mL to about 1.5 x 10 11 vg mL.
- the effective concentration is about 1.5 x 10 1J vg/mL.
- the effective concentration is about 1 .5 x 10" vg/mL.
- the effective concentration is about 2.8 x 10 J 1 vg/mL.
- the effective concentration is about 1.5 x 10 " vg/mL.
- the effective concentration is about 1 .5 x 10 l3 vg/mL.
- the lowest effective concentration of vims be utilized in order to reduce the risk of undesirable effects, such as toxicity, retinal dysplasia and detachment.
- Still other dosages in these ranges may be selected by the attending physician, taking into account the physical state of the subject, preferably human, being treated, the age of the subject, the particular ocular disord er and the degree to which the disorder, if progressive, has developed.
- the invention provides various methods of preventing, treating, arresting progression of or ameliorating the above-described ocular diseases and retinal changes associated therewith.
- the methods include administering to a mammalian subject in need thereof, an effective amount of a composition comprising a recombinant adeno- associated virus (AAV) carrying a nucleic acid sequence encoding a normal RPGR gene, or fragment thereof, under the control of regulator sequences which express the product of the gene in the subject's ocular cells, and a pharmaceutically acceptable carrier.
- AAV recombinant adeno- associated virus
- XLRP is associated with many retinal changes. These include a loss of photoreceptor structure or function; thinning or thickening of the outer nuclear layer (ONL); thinning or thickening of the outer plexiform layer (OPL);
- the invention provid es a method of preventing, arresting progression of or ameliorating any of the retinal changes associated with XLRP. As a result, the subject's vision is improved, or vision loss is arrested and/or ameliorated.
- the invention provides a method of preventing, arresting progression of or ameliorating vision loss associated with retinitis pigmentosa in the subject.
- Vision loss associated with retinitis pigmentosa refers to any decrease in peripheral vision, central (reading) vision, night vision, day vision, loss of color perception, loss of contrast sensitivity, or reduction in visual acuity.
- the invention provides a method to prevent, or arrest photoreceptor function loss, or increase photoreceptor function in the subject.
- Photoreceptor function may be assessed using the functional studies described above and in the examples below, e.g., ERG or perimetry, which are conventional in the art.
- photoreceptor function loss means a decrease in photoreceptor function as compared to a normal, non-diseased eye or the same eye at an earlier time pointAs used herein, "increase photoreceptor function” means to improve the function of the photoreceptors or increase the number or percentage of functional photoreceptors as compared to a diseased eye (having the same ocular disease), the same eye at an earlier time point, a non-treated portion of the same eye, or the contralateral eye of the same patient.
- the invention provides method of improving photoreceptor structure in the subject.
- “improving photoreceptor structure” refers (in the region of the retina that is treated) to one or more of an increase or decrease in outer nuclear layer (ONL) thickness, or arresting progression of ONL thickening or thinning, across the entire retina, in the central retina, or the periphery; increase or decrease in outer plexiform layer (OPL) thickness, or arresting progression of OPL thickening or thinning, across the entire retina, in the central retina, or the periphery; decrease in rod and cone inner segment (IS) shortening; decrease in shortening and loss of outer segments (OS); decrease in bipolar cell dendrite retraction, or an increase in bipolar cell dendrite length or amount; and reversal of opsin mislocalization.
- ONL outer nuclear layer
- OPL outer plexiform layer
- the invention provides a method of preventing, arresting progression of or ameliorating abnormalities of the outer plexiform layer (OPL) in a subject in need, thereof.
- OPL outer plexiform layer
- to ameliora te abnormalities of the OPL means (in the region of the retina that is treated) to increase or decrease the OPL thickness, or arrest of OPL thickenss changes, across the entire retina, in the central retina, or the periphery .
- the invention provides a method of increasing, decreaseing or preserving ONL thickness associated with X-linked form of retinitis pigmentosa (XLRP) in a subject in need thereof. Progressive ONL thinning is common in ail phenotypes of XLRP, and is sometimes proceeded by abnormal ONL thickening As used herein,
- the invention provides a method of preventing, arresting progression of or ameliorating bipolar cell dendrite retraction in a subject in need thereof. In the course of XLRP progression, bipolar cell dendrites retract and fail to connect with photoreceptor cells.
- the invention provides a method of preventing, arresting progression of or ameliorating or improving bipolar cell function loss in a subject in need thereof. Enhancement of biolar cell function also leads to improved scotopic (rod mediated) ERG b-wave amplitudes.
- the invention provides a method of improving post recepioral responses for rods and cones as recorded by ERG.
- the invention provides a method of preventing, arresting progression of or ameliorating axonal injury characterized by overexpression of neurofilaments in a subject in need thereof.
- the invention provides a method of preventing X-linked retinitis pigmentosa (XLRP) in a subject at risk of developing said disease.
- Subjects at risk of dev eloping XLRP include those with a family history of XLRP, those with one or more confirmed mutations in the RPGR gene, offspring of female carriers of an RPGR mutation (heterozygous females), offspring of females carrying an RPGR mutation on both X chromosomes.
- the invention provides a method of preventing, arresting progression of or ameliorating rod and/or R-'G cone opsin mislocalization in a subject in need thereof.
- rhodopsin and R/G cone opsin are found predominantly in membranes of the rod cell outer segment but become mislocaiized to the inner segment, ONL and/or the synaptic terminals in many retinal diseases and injuries, including XLRP.
- the invention provides a method of preventing, arresting or ameliorating the increase in phagocytic cells in the subretinal space at later stages of the disease. See, Beltran et ai, IOVS (2006) 47: 1669-81, incorporated herein by reference herein.
- the invention provides a method of preventing, arresting progression of or ameliorating OPL synaptic changes, bipolar cell abnormalities or inner retinal abnormalities associated with XLRP in a subject in need thereof.
- OPL synaptic changes include narrowing of the OPL associated with compressed photoreceptor synaptic terminals, and a reduction of the number of QBP2 -labeled synaptic ribbons in rod and cone terminals.
- Bipolar cell abnormalities include retraction of bipolar ceil dendrites.
- Inner retinal abnormalities include inner retinal hyperthickness, rod photoreceptor neurite sprouting, rod bipolar cell dendrite retraction, increased.
- GABA-immunoreactive amacrine cells and changes in Mulier glial cell reactivity, flattening of the axonal arborization of horizontal ceils that can be labeled with a calbindin antibody; thinning and loss of lamination (at later stages of disease) of the inner plexiform layer (IPL) that can be labled with GABA antibody.
- IPL inner plexiform layer
- the treatment may be used to prevent the occurrence of retinal damage or to rescue eyes having mild or advanced disease.
- the term "rescue" means to prevent progression of the disease to total blindness, prevent spread of damage to uninjured photoreceptor cells or to improve damage in injured photoreceptor cells.
- the composition is administered before disease onset.
- the composition is administered after the initiation of opsin mislocalization.
- the composition is administered prior to the initiation of photoreceptor loss.
- the composition is administered after initiation of photoreceptor loss.
- the composition is administered when less than 90% of the photoreceptors are functioning or remaining, as compared to a non-diseased eye.
- the composition is administered when less than 80% of the photoreceptors are functioning or remaining. In another embodiment, the composition is administered, when less than 70% of the photoreceptors are functioning or remaining. In another embodiment, the composition is administered when less than 60% of the photoreceptors are functioning or remaining. In another embodimeiU, the composition is administered when less than 50% of the photoreceptors are functioning or remaining. In another embodiment, the composition is administered when less than 40% of the photoreceptors are functioning or remaining. In another embodiment, the composition is administered when less than 30% of the photoreceptors are functioning or remaining. In another embodiment, the composition is administered when less than 20% of the photoreceptors are functioning or remaining.
- the composition is administered when less than 10% of the photoreceptors are functioning or remaining. In one embodiment, the composition is administered only to one or more regions of the eye, e.g., those which have retained photoreceptors. In another embodiment, the composition is administered to the entire eye.
- a method of treating or preventing XLRP in a subject in need thereof includes identifying a subject having, or at risk of developing, XLRP; performing genotypic analysis and identifying at least one mutation in the RPGR gene; performing non-invasive retinal imaging and functional studies and identifying areas of retained photoreceptors to be targeted for therapy; and administering to the subject an effective concentration of a composition, whereby XLRP is prevented, arrested or ameliorated.
- the composition includes a recombinant virus carrying a nucleic acid sequence encoding a normal photoreceptor cell-specific gene under the control of a promoter sequence which expresses the product of the gene in the photoreceptor cells, and a pharmaceutically acceptable carrier.
- Genotypic analysis is routine in the art and. may include the use of PGR to identify one or more mutations in the nucleic acid sequence of the RPGR gene. See, e.g., Meindl et al, Nat Gen, May 1996, 13:35, Vervoort, R. et al, 2000. Nat Genet 25(4): 462-466 (cited above); and Vervoort, R. and Wright, A.F. 2002. Human Mutation 19: 486-500, each of which is incorporated herein by reference.
- any of the above methods are performed utilizing a composition comprising a recombinant AAV2 5 pseudotyped adeno-associated vims, carrying a nucleic acid sequence encoding a ormal RPGR gene, or fragment thereof, under the control of an IRBP or GRKl promoter which directs expression of the product of the gene in the photoreceptor cells of the subject, formulated with a carrier and additional components suitable for subretinal injection.
- the method includes performing functional and imaging studies to determine the efficacy of the treatment. These studies include ERG and in vivo retinal imaging, as described in the examples below. In addition visual field studies, perimetry and microperimetry, mobility testing, visual acuity, color vision testing may be performed.
- any of the above described methods is performed in combination with another, or secondary, therapy.
- the therapy may be any now known, or as yet unknown, therapy which helps prevent, arrest or ameliorate XLRP or any of the above-described effects associated therewith.
- the secondary therapy is Ciliary Neurotrophic Factor (CNTF). Sieving, P.A. et al, 2006. Proc Natl Acad Sci U S A 103(10): 3896-3901 , which is hereby incorporated by reference.
- the secondary therapy can be administered before, concurrent with, or after administration of the rAAV described above.
- an exemplary hRPGRQRP ' 15 was employed in in vivo experiments to provide evidence of the utility and efficacy of the methods and compositions of this invention.
- the examples demonstrated restoration of retinal function by the method of this invention in a large animal model of a human retinopathy.
- the use of the exemplary vector demonstrated, in the experiments that the defect in the RPGR mutant dogs could be corrected by gene delivery. Retinal function was improved in this large animal model of blindness. This data allow one of skill in the art to readily anticipate that this method may be similarly used in treatment of XLRP or other types of retinal disease in other subjects, including humans.
- a full length human RPGRORF15 was cloned into AAV2/5 viral vectors and regulated by the human IRBP or GRK1 promoters.
- the vector cDNA was a full length human RPGRORF 15 clone, based on the sequence published by Alan Wright and.
- SEQ ID NO: 1 the sequence used in the construct (SEQ ID NO: 1) exhibits greater stability than the Wright sequence.
- This construct contains exons 1- ORF15, and was generated using 3-way ligation by step-wise amplifying exons l-part of 15b (nucleotides 169-1990) from human lymphocytes and 1991-3627 from human genomic DNA.
- An interna! restriction enzyme site Ndel (CATA ' TG) was created by site- directed mutagenesis at residue 1993 (A>T).
- the RPGRORF 15 sequence used in the constructs is shown in SEQ ID NO: 1 .
- An alignment of the nucleic acid sequence published by Alan Wright and colleagues (BK00571 1) and SEQ ID NO: 1 is provided in Figure 3 (See, also the aligned amino acid sequences encoded by the two nucleic acid sequences in Figure 4, and a partial consensus sequence illustrated in Figure 5). These fragments were then cloned in BamHI and XhoT sites in pBkiescript, propagated in E. colt Stbl4 and. sequence- verified at the University of Michigan DNA sequencing core facility.
- the human G-protein-coupied receptor protein kinase 1 (hGRKl) promoter was used to primarily control rod expression in the dog retina at a therapeutic concentration of 10 11 vg/ml; higher concentrations (10 13 ) result in expression in some cones, but with adverse retinal effects. Expression in both rods and cones was regulated by 235 bp of the human IRBP promoter that contains the important cis-acting element identified in the mouse proximal promoter. See, al-Ubaidi MR, et al. (1992), J Cell Biol 1 19: 1681 -1687 and Boatright JH, et al. (1997) Mol Vis 3: 15, both incorporated by reference herein.
- Vectors with this promoter result in GFP expression in both rods and cones in a dose and time dependent manner (Fig. 84 of Beltran 2012 which is reproduced as Fig 8 of US Provisional Patent Application No. 61/670,355). Vector DNA sequences were confirmed for accuracy before vector production.
- the two-plasmid co-transfection method was used to produce the AAV2/5 vector (See, Zolotukhin S, et al. (1999) Gene Tlier 6:973-985 which is incorporated by reference herein).
- Viral particles were titered and resuspended in balanced salt solution (BSS, Alcon Laboratories, Fort Worth, TX) containing 0. 014% Tween-20 at a concentration of 1.5x10 viral vector genomes per mL (vg/mi). Sterility and the lack of endotoxin were confirmed in the final product.
- Subretinal injections were performed under general anesthesia as previously published (See, e.g., Beltran WA, et al. (2010) Gene Ther. 17: 1 162-1 174 and omaromy AM, et al. (2010) Hum Mol Genet 19:2581-2593, both incorporated by reference herein).
- the volume injected was dependent on age/eye size: 70 ⁇ and 150 ⁇ , respectively, at 5 and 28 wks of age, with the therapeutic vector injected in the right eye, and BSS injected in the left.
- the location and extent of the subretinal blebs were recorded on fundus photographs or schematic fundus illustrations; in all cases the blebs flattened and the retina reattached within 24 hrs. Failed subretinal injection that refluxed. into the vitreous was found in one dog that was maintained throughout the study to determine potential therapeutic efficacy and/or ocular complications by the i travitreal route.
- Overlapping en face images of reflectivity with near-infrared, illumination (820 nm) were obtained.
- HRA2 or Spectralis HRA or Spectralis HRA+OCT, Heidelberg, Germany with 30° and 55° diameter lenses to delineate fundus features such as optic nerve, retinal blood vessels, boundaries of injection blebs, retinotomy sites and. other local changes.
- Custom programs (MatLab 6.5; The MathWorks, Natick, MA) were used to digitally stitch individual photos into a retina-wide panorama.
- short-wavelength (488 nm) illumination was used to delineate the boundary of the tapetum and pigmented.
- RPE Spectral-domain optical coherence tomography
- SD-OCT was performed with linear and raster scans (RTVue-100, Optowe, Inc. Fremont, CA or Spectralis HRA+OCT, Heidelberg,
- Post-acquisition processing of OCT data was performed with custom programs (MatLab 6.5; The Math Works, Natick, MA).
- integrated backscatter intensity of each raster scan was used to locate its precise location and orientation relative to retinal features visible on the retina wide mosaic formed by MR reflectance images.
- Individual LRPs forming all registered, raster scans were allotted to regularly spaced bins (1° x 1°) in a rectangular coordinate system centered at the optic nerve; LRPs in each bin were aligned and averaged.
- Intraretinal peaks and boundaries corresponding to histologically definable layers were segmented semi-automatically with manual override using both intensity and slope information of backscatter signal along each LRP.
- the retina-vitreous interface, OPL, outer limiting membrane (OLM), signal peak near the inner/outer segment (IS/OS) junction, and the RPE were defined.
- OPL outer limiting membrane
- IS/OS inner/outer segment
- RPE signal peak near the inner/outer segment
- ONL thickness was defined from the scierad transition of the OPL to the OLM, and ONL thickness topography was calculated.
- the topography of IS/OS backscatter intensity was calculated by first measuring the mean backscatter intensity within ⁇ 8 ⁇ of the IS/OS peak and then normalizing this value by the mean backscatter intensity of the first 75 ⁇ of retina scierad to the retina-vitreous interface. For all topographic results, locations of blood vessels, optic nerve head and bleb boundaries were overlaid for reference. Further quantitative comparisons were achieved by sampling the ONL thickness of a 10° wide band along the vertical meridian crossing the optic nerve head.
- Dogs were dark-adapted overnight, premedicated, and anesthetized as described (Acland GM, et al. (2001) Nature Genetics 28:92-95; Kijas JW, et al. (2002) Proc Natl Acad Sci U S A 99:6328-6333. both of which are incorporated by reference herein).
- Pupils were dilated with atropine (1 %), tropicamide (1%) and phenylephrine (10%). Pulse rate, oxygen saturation, and temperature were monitored.
- Full-field ERGs were recorded with Burian-Allen (Hansen Ophthalmics, Iowa City, 1A) contact lens electrodes and a computer-based system.
- Assessment of visual behavior using qualitative or quantitative measures was not performed in treated animals because, at the disease stages studied, both mutant strains (untreated) retain sufficient rod and cone visual function that the are not distinguishable from normal
- an antibody directed at the C-terminal domain of human RPGR was used to identify the therapeutic transgene in treated eyes.
- the antigen-antibody complexes were visualized, with fluorochrome-labeled secondary antibodies (Alexa Fluor, 1 :200; Molecular Probes, Eugene, OR, USA ⁇ with DAPI to label cell nuclei, and digital images taken (Spot 4.0 camera, Diagnostic Instruments, Sterling Heights, MI), and imported into a graphics program (Photoshop; Adobe, Mountain View, CA, US A) for display.
- Example 2 RPGR ORF15 mutations lead, to photoreceptor degeneration in humans and dogs
- Topography of photoreceptors can be mapped across the retina of patients with RPGR-XLRP by measuring the thickness of the outer (photoreceptor) nuclear layer (ONL) using cross-sectional OCT retinal imaging.
- OCT retinal imaging As shown in Figure 1A of Beltran WA, et al, (2012 Jan) Proc Natl Acad Sci USA, 109(6):2132-7 (Beltran 2012), which is reproduced as Fig 1A of US Provisional Patent Application No. 61 /670,355, in normal eyes (inset), ONL, thickness peaks centrally and declines with, distance from the fovea.
- XLRP patients with ORF 15 mutations can have different disease patterns.
- RPGR disease expression also includes the less common phenotype characterized by loss of central photoreceptors and diseased, yet better preserved, peripheral photoreceptors (Fig. lA of Beltran 2012 which is reproduced as Fig 1A of US Provisional Patent Application No, 61/670,355).
- the present examples taken together with previous observations, demonstrate there can be a spectrum of human RPGR-XLRP phenotypes. Most of the phenotypes have rod more than cone dysfunction by ERG.
- the two canine models can also be studied with cross-sectional retinal imaging, such as we used for human patients, and topographical photoreceptor maps generated and compared with normal data (Fig. I B of Beltran 2012 which is reproduced as Fig IB of US Provisional Patent Application No. 61/670,355).
- a spectrum of disease patterns also occurs in the canine models.
- XLPRAl dogs for example, can show ONL thinning with relative preservation of a region immediately superior to the optic nerve, corresponding to the high photoreceptor density of the visual streak.
- an example of an XLPRA2 photoreceptor map shows a pattern of retina- wid e ONL thinning, but more pronounced losses in the central retina, corresponding to the visual streak, than in peripheral retina.
- XLPRA1 at younger ages shows ONL thickness that is within or near normal limits (Fig. C of Beltran 2012 which is reproduced as Fig IC of US Provisional Patent Application No. 61/670,355).
- Fig. lC brackets, of Beltran 2012 which is reproduced as Fig I C of US Provisional Patent Application No. 61/670,355
- Both XLPRA 1 and XLPRA2 diseases could be characterized as having more rod than cone dysfunction.
- Example 3 Treatment of XLPRA with gene knockdown and replacement strategy - in vivo findings
- RNA was encoded into a construct containing a canine shortened RPGRORF 15 cD A, which has had 708 bp removed in frame from the repetitive region of ORF15 (cRPGR-short). Additional silent mutations were included, in the cRPGR sequence to "harden" the sequence to the siRNA.
- Subretinal injection of the cRPGR « h 0 rt cDNA under the control of hIRBP promoter (AAV2/5-MRBP- cRPGRshort -shRN A5) was performed in XLPRA2 dogs. Treatment was initiated at 5 weeks, after disease onset. Severe retinal lesions of retinal dysplasia were observed at 17 weeks following sub-retinal injection. No rescue was seen (Table 2).
- Provisional Patent Application No. 61/670,355) demonstrates that AAV2/5 vector with hIRBP promoter targets expression to rods and cones.
- This figure shows native GFP fluorescence (green) in normal canine retina 2 and 8 wks following subretinal injection of AAV2/5-hIRBP-hGFP. 150 ⁇ injections of 2 vector titers were used. GFP fluorescence in photoreceptors is present by 2 wks (Al , A2), and is increased at 8 wks (Bl , B2).
- the positive treatment response was detectable in vivo.
- Treated eyes of XI.PRA 1 dogs had thicker ONL in the superior peripheral retina, specifically on the treated side of the subretinal injection area (bleb) boundar compared to the untreated side (Fig.2A of Beltran 2012 which is reproduced as Fig 2A of US Provisional Patent Application No. 61/670,355).
- the signal peak corresponding to the region of photoreceptor inner and outer segments (IS/OS) was more intense and better organized on the treated side (Fig.2A of Beltran 2012 which is reproduced as Fig 2A of US Provisional Patent Application No. 61/670,355).
- Treated eyes of XLPRA2 dogs showed thicker ONL on the treated side or higher intensity signal at the level of the IS/OS (Fig.2A of Beltran 2012 which is reproduced as Fig 2A of US Provisional Patent Application No. 61/670,355).
- Fig.2A of Beltran 2012 which is reproduced as Fig 2A of US Provisional Patent Application No. 61/670,355
- Fig.2B of Beltran 2012 which is reproduced as Fig 2B of US Pro visional Patent Application No. 61 /670,355
- XLPRA1 dog H484 at 76 weeks of age had a clearly demarcated zone of ONL retention within the treatment bleb in superior peripheral retina (Fig.
- XLPRA1 dog H483 with a smaller subretinai bleb had similar findings in the superior peripheral region with local evidence of ONL thickness retention inside the bleb boundary. More centrally, both treated and untreated regions retained near normal ONL thickness and there was no change in ONL thickness corresponding to the bleb boundary (Fig.2B of Beltran 2012 which is reproduced as Fig 2B of US Provisional Patent
- XLPRA2 dog Z412 showed a region with preserved ONL that corresponded to the bleb boundary; ONL, was abnormally thinned outside this boundary (Fig.2B of Beltran 2012 which is reproduced as Fig 2B of US Provisional Patent Application No. 61/670,355). Longitudinal follow-up from 21 to 36 wks showed the time course of ONL degeneration outside the bleb of the treated eye and in the BSS-injected control eye (Fig.S l of Beltran 20 2 which is reproduced as Fig 5 of US Provisional Patent Application No. 61/670,355). XLPRA2 dog Z414 showed a region of slight ONL thickness retention approximately corresponding to the bleb boundary (Fig.2B of Beltran 2012 which is reproduced as Fig 2B of US Provisional Patent Application No.
- Fig. 2C hashed, of Beltran 2012 which is reproduced as Fig 2C of US Provisional Patent Application No. 61/670,355).
- ERGs were evaluated in terms of inter ocular asymmetry (Fig. 2D of Beltran 2012 which is reproduced as Fig 2D of US Provisional Patent Application No, 61/670,355).
- Signals were larger in the treated eyes of three dogs (H484, Z412 and Z414) for photoreceptor responses dominated by rods, and for post-receptoral bipolar cell responses mediated by both rods and cones.
- H483 had the least degenerate retina and normal amplitude responses bilaterally (Figs. 2D and S2 of Beltran 2012 which is reproduced as Figs 2D and 6 of US Provisional Patent Application No. 61/670,355) that were symmetric for cones and asymmetric for rods, favoring the untreated eye.
- AAV2/5 vector injections had a titer of 1.5x1011 vg tnl.
- Dog Z413 had 70 ⁇ injected into the vitreous and served as control.
- OCT optical coherence tomography
- IS/OS inner segment/outer segment
- Outer plexiform layer OPL.
- Pre- and post-synaptic terminal structures including presence of normal elongated bipolar dendrites as determined by immunohistochemistry (IHC) using antibodies that label photoreceptor synaptic terminals and bipolar cells.
- IHC immunohistochemistry
- Example 5 Gene augmentation rescues photoreceptors and reverses mislocalization of rod and cone opsins in both XLPRA genotypes
- OPL and inner retinal abnormalities are common secondary effects.
- narrowing of the OPL was associated with compressed photoreceptor synaptic terminals (Panels 2, 5 in Figs. 3 and S3 of Beltran 2012 which are reproduced as Figs 3 and 7 of US Provisional Patent Application No, 61/670,355), and a reduction of the number of CtBP2-labeled synaptic ribbons in rod and cone terminals (Panels 1, 2 in Figs. 4 and S4 of Beltran 2012 which are reproduced as Figs 4 and 8 of US Provisional Patent Application No. 61/670,355).
- GFAP irnmunolabeling clearly delineated untreated regions that showed increased Muller glia reactivity, whereas it diminished in the transition zone between treated and untreated, regions, and was absent in the bleb area (Panels 7, 8 in Figs. 4 and S4 of Beltran 2012 which are reproduced as Figs 4 and 8 of US Provisional Patent Application No. 61 /670,355).
- inner retinal rescue was complete in 3 of 4 treated eyes; rescue was partial for the one treated with AAV2/5-hGRKl -hRPGR where rod neurite sprouting extended into the inner retina (Table 1 ), and NF200 labeling pattern was intermediate between normal and disease (Fig.
- XLRP is among candidate diseases for treatment because it can be identified in the clinic, either through pedigree analysis, carrier identification or by the fact that there is a high frequency of XLRP among simplex males with. RP; and mutations in RPGROR.F.15 account for about 75% of XLRP patients.
- RPGRORF 15-XLRP strongly suggest that a gene augmentation strategy is a viable option for this photoreceptor ciliopathy, and complements successful rod rescue in a murine model of the Bardet-Biedl syndrome ciliopathy.
- the disease in humans and in animal models is not, however, without complexity and future therapy of the human disease will need, to be approached with caution.
- there are modifiers that may affect disease expression in both patients and dog models and.
- the phenotypic diversity may be a potential obstacle to patient selection, and points to the need for more than a molecular diagnosis and patient's age as criteria to determine candidacy for treatment.
- genotype data In support of genotype data there must be complementing detailed non-invasive retinal imaging and function studies. The temptation should be resisted in early human treatment approaches to try to design a treatment to fit all phenotypes and all disease stages.
- the dog diseases are mainly rod>cone degenerations, and there was efficacy in treating both the severe XLPRA2 with central retinal degeneration, and the less severe XLPRA1 with central retinal preservation using vectors that targeted both rods and cones.
- certain human RPGR-XLRP phenotypes such as mild cone>rod or cone dystrophies.
- Some patients can show very limited or even normal rod function, and cone targeting strategies must be developed for these subtypes.
- Proof-of-principle studies targeting cone diseases already have been successful in both mouse and. dog models with mutations in cone phototransduction or cyclic GMP channel genes, so translation to the clinic would be expedited.
- RPGR-associated disease is common and generally severe, the function of the gene, and the association between mutation and disease are less well understood.
- RPGR has a complex splicing pattern with multiple tissue-/cell-specific isoforms, is known to interact with a number of ciliary proteins, acts as a gunanine nucleotide exchange factor for small GTPase RAB8A and may have a role in vertebrate development.
- Such complexity may account partially for the variability in disease phenotype.
- loss of function or gain of function mechanisms have been proposed, a suggestion that each would require different therapeutic approaches.
- hIRBP promoter that regulates expression of the therapeutic gene results in robust expression of reporter or therapeutic genes in both cell types (Fig.SS and Panels 6-8 in Figs. 3 and S3 of Beitran 2012 which are reproduced as Figs 9, 2 and 7, respectively, of US Provisional Patent Application No. 61/670,355), and expression is sustained.
- IRBP also is expressed in human cones, we expect efficient targeting of rods and cones with this promoter in future transiational studies.
- the therapeutic transgene expression was low in rods, and to a lesser extent in cones.
- a characteristic feature of photoreceptor degenerations is progressi ve changes in the OPL, bipolar cells and inner retinal layers. These were widespread in untreated areas, but reversed, to normal in treated areas, particularly when the AAV2/5- hIRPB-hRPGR v ector was used. Prevention of remod eling occurred when treating XLPRAI retinas prior to disease onset, while in XLPRA2, early OPL synaptic changes, bipolar cell
- Example 8 Corrective gene therapy for RPGR-XLRP rescues canine model at mid-stage disease.
- AAV2/5 vector construct (titer: 1.51 x 10 ! ! vg/mi) carrying full-length human RPGRORF 15 cDNA under the control of a hIRBP promoter was injected subretinally in three 12-wk-old XLPRA2 dogs. At that age, there is on-going cell death and the ONI, thickness is reduced by ⁇ 40%.
- one XLPRA2 dog was injected shortly after the onset of disease (5.1 wks of age) as an early disease stage control. Contra-lateral eyes were either injected with BSS, or received a similar dose of viral construct intravitreally. Photoreceptor structure and function was assessed by means of non-invasive retinal imaging (cSLO/ SD-OCT) and ERG at 39 and 42 weeks of age. respectively.
- Petrs-Silva H, et al (201 1) Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 19:293-301.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/413,884 US9770491B2 (en) | 2012-07-11 | 2013-01-23 | AAV-mediated gene therapy for RPGR X-linked retinal degeneration |
CA2878171A CA2878171C (en) | 2012-07-11 | 2013-01-23 | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
EP13816245.8A EP2872183B1 (en) | 2012-07-11 | 2013-01-23 | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
CN201380045636.1A CN105120901A (en) | 2012-07-11 | 2013-01-23 | AAV-mediated gene therapy for RPGR X-linked retinal degeneration |
NZ704275A NZ704275A (en) | 2012-07-11 | 2013-01-23 | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
AU2013287281A AU2013287281B2 (en) | 2012-07-11 | 2013-01-23 | AAV-mediated gene therapy for RPGR x-linked retinal degeneration |
JP2015521593A JP6199965B2 (en) | 2012-07-11 | 2013-01-23 | AAV-mediated gene therapy for RPGRX-linked retinal degeneration |
US15/699,262 US10383922B2 (en) | 2012-07-11 | 2017-09-08 | AAV-mediated gene therapy for RPGR X-linked retinal degeneration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670355P | 2012-07-11 | 2012-07-11 | |
US61/670,355 | 2012-07-11 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/413,884 A-371-Of-International US9770491B2 (en) | 2012-07-11 | 2013-01-23 | AAV-mediated gene therapy for RPGR X-linked retinal degeneration |
US15/699,262 Division US10383922B2 (en) | 2012-07-11 | 2017-09-08 | AAV-mediated gene therapy for RPGR X-linked retinal degeneration |
US15/699,262 Continuation US10383922B2 (en) | 2012-07-11 | 2017-09-08 | AAV-mediated gene therapy for RPGR X-linked retinal degeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014011210A1 true WO2014011210A1 (en) | 2014-01-16 |
Family
ID=49916455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/022628 WO2014011210A1 (en) | 2012-07-11 | 2013-01-23 | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
Country Status (8)
Country | Link |
---|---|
US (2) | US9770491B2 (en) |
EP (1) | EP2872183B1 (en) |
JP (1) | JP6199965B2 (en) |
CN (1) | CN105120901A (en) |
AU (1) | AU2013287281B2 (en) |
CA (1) | CA2878171C (en) |
NZ (1) | NZ704275A (en) |
WO (1) | WO2014011210A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015160893A1 (en) * | 2014-04-15 | 2015-10-22 | Applied Genetic Technologies Corporation | Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) |
WO2016001693A1 (en) * | 2014-07-04 | 2016-01-07 | Ucl Business Plc | Rpgr-orf15 variant gene in the treatment of retinitis pigmentosa |
WO2016014353A1 (en) | 2014-07-24 | 2016-01-28 | Massachusetts Eye & Ear Infirmary | Rpgr gene therapy for retinitis pigmentosa |
WO2016145345A1 (en) * | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rp2 and rpgr vectors for treating x-linked retinitis pigmentosa |
WO2016193434A1 (en) * | 2015-06-04 | 2016-12-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Improved methods for treating ocular diseases by gene therapy |
JP2017509632A (en) * | 2014-03-21 | 2017-04-06 | ジェンザイム・コーポレーション | Gene therapy for retinitis pigmentosa |
WO2017106202A2 (en) | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
EP3265568A4 (en) * | 2015-03-06 | 2018-08-08 | Massachusetts Eye & Ear Infirmary | Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene |
WO2018218359A1 (en) | 2017-05-31 | 2018-12-06 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating peroxisomal disorders |
US10836803B2 (en) | 2015-09-10 | 2020-11-17 | Oxford University Innovation Limited | Treatment of retinitis pigmentosa |
EP3710590A4 (en) * | 2017-11-15 | 2021-06-23 | The Regents of The University of Michigan | Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies |
US11091776B2 (en) | 2016-04-15 | 2021-08-17 | The Trustees Of The University Of Pennsylvania | AAV8 mutant capsids and compositions containing same |
US11197936B2 (en) | 2016-07-08 | 2021-12-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treatment of disorders and diseases involving RDH12 |
WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
US11564996B2 (en) | 2017-03-01 | 2023-01-31 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
US11827898B2 (en) | 2017-06-14 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
US11879133B2 (en) | 2017-04-24 | 2024-01-23 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014011210A1 (en) * | 2012-07-11 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
EP3377116A4 (en) | 2015-11-19 | 2019-07-10 | The Trustees of The University of Pennsylvania | Compositions and methods for correction of heritable ocular disease |
AU2019255708A1 (en) | 2018-04-17 | 2020-11-26 | Ascidian Therapeutics, Inc. | Trans-splicing molecules |
CN113952472A (en) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | Compositions and methods for treating ocular diseases |
IL300785A (en) | 2020-09-02 | 2023-04-01 | 4D Molecular Therapeutics Inc | Codon optimized rpgrorf 15 genes and uses thereof |
CN117165596A (en) * | 2022-05-27 | 2023-12-05 | 武汉纽福斯生物科技有限公司 | Nucleic acid encoding RPGR and uses thereof |
WO2024013224A2 (en) * | 2022-07-14 | 2024-01-18 | Fondation Asile Des Aveugles | Gene therapy for fam161a-associated retinopathies and other ciliopathies |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002089857A2 (en) * | 2001-05-08 | 2002-11-14 | Tranzyme, Inc. | Trans-viral vector mediated gene transfer to the retina |
US20100272688A1 (en) * | 2001-04-13 | 2010-10-28 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
AU1282895A (en) | 1993-12-29 | 1995-07-17 | Sumitomo Pharmaceuticals Company, Limited | Novel human ciliary neurotrophic factor |
JP3768257B2 (en) * | 1993-12-29 | 2006-04-19 | 大日本住友製薬株式会社 | Modified protein |
US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
EP1453547B1 (en) | 2001-12-17 | 2016-09-21 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor |
SI2311848T1 (en) | 2002-12-23 | 2013-11-29 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
ES2411479T3 (en) | 2003-09-30 | 2013-07-05 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus clades (AAV), sequences, vectors that contain them, and uses thereof |
ES2331342B1 (en) * | 2006-05-22 | 2010-10-13 | Consejo Superior Investg.Cientificas | USE OF PROINSULIN FOR THE PREPARATION OF A NEUROPROTECTING PHARMACEUTICAL COMPOSITION, THERAPEUTIC COMPOSITION CONTAINING IT AND ITS APPLICATIONS. |
WO2009100253A1 (en) * | 2008-02-07 | 2009-08-13 | Ceregene, Inc. | Rescue of photoreceptors by intravitreal administation of an expression vector encoding a therapeutic protein |
WO2009105690A2 (en) * | 2008-02-21 | 2009-08-27 | Targeted Genetics Corporation | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
US7561973B1 (en) | 2008-07-31 | 2009-07-14 | Dna Twopointo, Inc. | Methods for determining properties that affect an expression property value of polynucleotides in an expression system |
US7561972B1 (en) | 2008-06-06 | 2009-07-14 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
ITMI20090284A1 (en) * | 2009-02-26 | 2010-08-27 | Consiglio Nazionale Ricerche | USE OF INHIBITORS OF SERINA PALMITOILTRASFERASI FOR THE PREVENTION AND DECELERATION OF HEREDITIC RETINAL DEGENERATIONS AND RELATIVE COMPOSITIONS |
GB0911870D0 (en) * | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
WO2014011210A1 (en) * | 2012-07-11 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
-
2013
- 2013-01-23 WO PCT/US2013/022628 patent/WO2014011210A1/en active Application Filing
- 2013-01-23 CA CA2878171A patent/CA2878171C/en active Active
- 2013-01-23 US US14/413,884 patent/US9770491B2/en active Active
- 2013-01-23 JP JP2015521593A patent/JP6199965B2/en active Active
- 2013-01-23 EP EP13816245.8A patent/EP2872183B1/en active Active
- 2013-01-23 CN CN201380045636.1A patent/CN105120901A/en active Pending
- 2013-01-23 AU AU2013287281A patent/AU2013287281B2/en active Active
- 2013-01-23 NZ NZ704275A patent/NZ704275A/en unknown
-
2017
- 2017-09-08 US US15/699,262 patent/US10383922B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100272688A1 (en) * | 2001-04-13 | 2010-10-28 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
WO2002089857A2 (en) * | 2001-05-08 | 2002-11-14 | Tranzyme, Inc. | Trans-viral vector mediated gene transfer to the retina |
Non-Patent Citations (3)
Title |
---|
BELTRAN ET AL.: "A Frameshift Mutation in RPGR Exon ORF15 Causes Photoreceptor Degeneration and Inner Retina Remodeling in a Model of X-Linked Retinitis Pigmentosa.", IOVS, vol. 47, no. 4, April 2006 (2006-04-01), pages 1669 - 1681, XP055180990 * |
BELTRAN ET AL.: "Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa.", PNAS, vol. 109, no. 6, 7 February 2012 (2012-02-07), pages 2132 - 2137, XP055155762 * |
SCHMID ET AL.: "Mutation and tissue-specific alterations of RPGR transcripts.", IOVS PAPERS IN PRESS. MANUSCRIPT IOVS.09-4031., October 2009 (2009-10-01), pages 1628 - 1635, XP055180993 * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020059737A (en) * | 2014-03-21 | 2020-04-16 | ジェンザイム・コーポレーション | Gene therapy for retinitis pigmentosa |
JP7048563B2 (en) | 2014-03-21 | 2022-04-05 | ジェンザイム・コーポレーション | Gene therapy for retinitis pigmentosa |
JP2017509632A (en) * | 2014-03-21 | 2017-04-06 | ジェンザイム・コーポレーション | Gene therapy for retinitis pigmentosa |
US10383953B2 (en) | 2014-03-21 | 2019-08-20 | Genzyme Corporation | Gene therapy for retinitis pigmentosa |
US11103598B2 (en) | 2014-03-21 | 2021-08-31 | Genzyme Corporation | Gene therapy for retinitis pigmentosa |
EP3132051A4 (en) * | 2014-04-15 | 2017-11-29 | Applied Genetic Technologies Corporation | Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) |
US20150353938A1 (en) * | 2014-04-15 | 2015-12-10 | Applied Genetic Technologies Corporation | Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) |
WO2015160893A1 (en) * | 2014-04-15 | 2015-10-22 | Applied Genetic Technologies Corporation | Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) |
US9534225B2 (en) | 2014-04-15 | 2017-01-03 | Applied Genetic Technologies Corporation | Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (RPGR) |
JP2017513484A (en) * | 2014-04-15 | 2017-06-01 | アプライド ジェネティック テクノロジーズ コーポレイション | Codon-optimized nucleic acid encoding retinitis pigmentosa GTPase regulator (RPGR) |
WO2016001693A1 (en) * | 2014-07-04 | 2016-01-07 | Ucl Business Plc | Rpgr-orf15 variant gene in the treatment of retinitis pigmentosa |
JP2017523239A (en) * | 2014-07-24 | 2017-08-17 | マサチューセッツ・アイ・アンド・イア・インファーマリー | RPGR gene therapy for retinitis pigmentosa |
CN107206105A (en) * | 2014-07-24 | 2017-09-26 | 麻省眼耳科医院 | The RPGR gene therapies of retinitis pigmentosa |
US11045558B2 (en) | 2014-07-24 | 2021-06-29 | Massachusetts Eye & Ear Infirmary | RPGR gene therapy for retinitis pigmentosa |
EP3821912A1 (en) * | 2014-07-24 | 2021-05-19 | Massachusetts Eye & Ear Infirmary | Rpgr gene therapy for retinitis pigmentosa |
US10314924B2 (en) | 2014-07-24 | 2019-06-11 | Massachusetts Eye & Ear Infirmary | RPGR gene therapy for retinitis pigmentosa |
JP2022009333A (en) * | 2014-07-24 | 2022-01-14 | マサチューセッツ・アイ・アンド・イア・インファーマリー | RPGR gene therapy for retinitis pigmentosa |
JP7198329B2 (en) | 2014-07-24 | 2022-12-28 | マサチューセッツ・アイ・アンド・イア・インファーマリー | RPGR gene therapy for retinitis pigmentosa |
WO2016014353A1 (en) | 2014-07-24 | 2016-01-28 | Massachusetts Eye & Ear Infirmary | Rpgr gene therapy for retinitis pigmentosa |
JP2020073536A (en) * | 2014-07-24 | 2020-05-14 | マサチューセッツ・アイ・アンド・イア・インファーマリー | RPGR gene therapy for retinitis pigmentosa |
EP3748007A1 (en) * | 2015-03-06 | 2020-12-09 | Massachusetts Eye & Ear Infirmary | Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene |
EP3265568A4 (en) * | 2015-03-06 | 2018-08-08 | Massachusetts Eye & Ear Infirmary | Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene |
US10646588B2 (en) | 2015-03-11 | 2020-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | RP2 and RPGR vectors for treating X-linked retinitis pigmentosa |
JP2018509154A (en) * | 2015-03-11 | 2018-04-05 | アメリカ合衆国 | RP2 and RPGR vectors for the treatment of X-linked retinitis pigmentosa |
US20200289670A1 (en) * | 2015-03-11 | 2020-09-17 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Rp2 and rpgr vectors for treating x-linked retinitis pigmentosa |
US11617801B2 (en) | 2015-03-11 | 2023-04-04 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Services | RP2 and RPGR vectors for treating X-linked retinitis pigmentosa |
WO2016145345A1 (en) * | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rp2 and rpgr vectors for treating x-linked retinitis pigmentosa |
AU2016228751B2 (en) * | 2015-03-11 | 2022-01-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rp2 vectors for treating x-linked retinitis pigmentosa |
JP2018522834A (en) * | 2015-06-04 | 2018-08-16 | インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) | Improved method for the treatment of eye diseases by gene therapy |
WO2016193434A1 (en) * | 2015-06-04 | 2016-12-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Improved methods for treating ocular diseases by gene therapy |
US10836803B2 (en) | 2015-09-10 | 2020-11-17 | Oxford University Innovation Limited | Treatment of retinitis pigmentosa |
US11090392B2 (en) | 2015-12-14 | 2021-08-17 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
EP3795180A1 (en) | 2015-12-14 | 2021-03-24 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
WO2017106202A2 (en) | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
US11091776B2 (en) | 2016-04-15 | 2021-08-17 | The Trustees Of The University Of Pennsylvania | AAV8 mutant capsids and compositions containing same |
US11197936B2 (en) | 2016-07-08 | 2021-12-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treatment of disorders and diseases involving RDH12 |
US11564996B2 (en) | 2017-03-01 | 2023-01-31 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
US11879133B2 (en) | 2017-04-24 | 2024-01-23 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
WO2018218359A1 (en) | 2017-05-31 | 2018-12-06 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating peroxisomal disorders |
US11793887B2 (en) | 2017-05-31 | 2023-10-24 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating peroxisomal disorders |
US11827898B2 (en) | 2017-06-14 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
EP3710590A4 (en) * | 2017-11-15 | 2021-06-23 | The Regents of The University of Michigan | Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies |
WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
Also Published As
Publication number | Publication date |
---|---|
EP2872183B1 (en) | 2018-09-26 |
US9770491B2 (en) | 2017-09-26 |
JP6199965B2 (en) | 2017-09-20 |
US10383922B2 (en) | 2019-08-20 |
EP2872183A1 (en) | 2015-05-20 |
CA2878171A1 (en) | 2014-01-16 |
US20180036385A1 (en) | 2018-02-08 |
NZ704275A (en) | 2016-09-30 |
CA2878171C (en) | 2021-04-27 |
AU2013287281B2 (en) | 2018-04-26 |
US20150202269A1 (en) | 2015-07-23 |
JP2015523379A (en) | 2015-08-13 |
EP2872183A4 (en) | 2015-12-09 |
CN105120901A (en) | 2015-12-02 |
AU2013287281A1 (en) | 2015-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10383922B2 (en) | AAV-mediated gene therapy for RPGR X-linked retinal degeneration | |
Beltran et al. | Optimization of retinal gene therapy for X-linked retinitis pigmentosa due to RPGR mutations | |
Pawlyk et al. | Replacement gene therapy with a human RPGRIP1 sequence slows photoreceptor degeneration in a murine model of Leber congenital amaurosis | |
US20190343920A1 (en) | Aav-mediated gene therapy for nphp5 lca-ciliopathy | |
AU2016355343A1 (en) | Compositions and methods for correction of heritable ocular disease | |
US20230233709A1 (en) | Gene therapy for ocular disorders | |
JP7101656B2 (en) | Methods and compositions for treating diseases and diseases involving RDH12 | |
JP2021019611A (en) | Rp2 and rpgr vectors for treating x-linked retinitis pigmentosa | |
Aguirre et al. | Gene therapy reforms photoreceptor structure and restores vision in NPHP5-associated Leber congenital amaurosis | |
JP2023116709A (en) | Gene therapy for ocular disorders | |
US20220175969A1 (en) | Enhanced human opsin promoter for rod specific expression | |
US11793887B2 (en) | Gene therapy for treating peroxisomal disorders | |
JP2023516637A (en) | Methods for treating and evaluating autosomal dominant bestrophinopathy | |
US20220143217A1 (en) | Neuroprotective gene therapy targeting the akt pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13816245 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2878171 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013816245 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015521593 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14413884 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013287281 Country of ref document: AU Date of ref document: 20130123 Kind code of ref document: A |